A 55-year-old woman with FIGO Stage IA Grade 1 endometrioid endometrial carcinoma (superficial myometrial invasion <50%, no LVSI) undergoes TAH-BSO. According to ESMO/ESGO/ESTRO 2021 risk stratification, she is in which risk group and what adjuvant treatment is recommended?
- A Intermediate risk — pelvic external beam radiotherapy recommended
- B High-intermediate risk — vaginal brachytherapy recommended
- C Low risk — no adjuvant therapy recommended ✓
- D High risk — carboplatin-paclitaxel chemotherapy recommended
Correct answer: C. Low risk — no adjuvant therapy recommended
Explanation
According to ESMO/ESGO/ESTRO 2021 guidelines, Stage IA Grade 1–2 endometrioid endometrial carcinoma without LVSI is classified as LOW RISK. No adjuvant treatment is recommended for low-risk patients because the recurrence risk is <5% and the benefit of radiotherapy does not outweigh the toxicity. High-intermediate risk (Stage IB Grade 1–2 without LVSI or Stage IA Grade 3 without LVSI) warrants vaginal brachytherapy. High risk warrants chemotherapy ± radiotherapy.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.